Medium impact
Cardioverter Defibrillators/Cardiac Resynchronization Therapy - Medicare Advantage (Revised)
Humana·Effective May 1, 2026
HCPCS C1896 is officially defined as "Lead, cardioverter-defibrillator, other than endocardial single or dual coil (implantable)." HCPCS C1896 is referenced in 1 tracked payer policy change from Humana. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS C1896 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Related
Get alerts for changes like this
Save a search and receive a daily digest whenever a new policy change matches your filters.